Test Searches require one of the following browsers: Google Chrome, Safari, or Firefox. This page WILL NOT WORK with Internet Explorer versions 8 or older.

Alphabetical Index
Calprotectin, Fecal (8000101671 (LAB001653))
Test Mnemonic:

CALPRO FEC
Specimen Requirements:
Collection:

Collect stool specimens into a clean airtight container without preservatives. 
Container:

Sterile container without preservative.
Minimum Volume:

1 mL for liquid stools or 1 gram for semi-solid and solid stools.
Storage/Transport:

Transport specimens refrigerated at 2-8°C; if delayed longer than 72 hours specimen should be frozen at - 20°C.
Stability:

Specimens are stable at 2-8°C for up to 72 hours, after this time the specimen should be stored at -20°C.
Causes for Rejection:

Specimens must meet criteria set forth in the Lab Services Specimen Labeling and Requests for Testing policy.

Improper collection. Specimen container unlabeled or labeled incorrectly. No date and time of collection or collector information on order.
Methodology:

Quantitative Chemiluminescent immunoassay (CLIA)
Performed:
Lab:

Clinical Microbiology
Turnaround Time:

96 hours
Reference Range:

Less than 50 µg/g
CPT 4 Code:

83993
Note:

Results should be utilized in conjunction with other clinical and laboratory data to assist the clinician in patient management decisions.

False negative results could occur in patients who have granulocytopenia due to bone marrow depression.

Results may not be clinically applicable to children less than two years of age who have mildly increased fecal Calprotectin levels.

There is a potential for elevated Calprotectin test results when measuring bloody stool samples.

Other intestinal diseases, including many gastrointestinal infections and colorectal cancer, can result in elevated levels of Calprotectin.
Synonyms:

Cal pro, Calpro, Fecal Calprotectin, IBD, IBS, Stool Calprotectin
Clinical Indication:

This test can be used as an aid in the diagnosis of inflammatory bowel disease (IBD), specifically Cronh's disease and ulcerative colitis, and as an aid in the differentiation of IBD from irritable bowel syndrome (IBS).
Effective Date: 12/12/2023
Reviewed By/Date: -
Approved By/Date: Williams-Bouyer, Natalie - 12/07/2023
When ordering tests for which Medicare or Medicaid reimbursement will be sought, physicians should only order tests that are medically necessary for the diagnosis or treatment of the patient. Components of the organ or disease panels may be ordered individually. The diagnostic information must substantiate all tests ordered and must be in the form of an ICD-10 code or its verbal equivalent.

« Back